STRIDE-III redraws treatment targets in inflammatory bowel disease care
The latest STRIDE-III recommendations mark a substantial recalibration of treat-to-target care in inflammatory bowel disease, separating goals that should drive treatment change from those that should mainly guide monitoring and optimisation. The updated framework for Crohn’s disease and ulcerative colitis arrives after new evidence accumulated across inflammatory, endoscopic, biomarker, and patient-centred outcomes following the STRIDE-II period. It is built not around a single end point, but around a hierarchy of targets that mirrors the way clinicians actually manage chronic relapsing intestinal inflammation: by deciding when to escalate therapy, when to watch closely, and when to focus on the patient’s lived experience of disease.
The update rested on a broad evidence review and a large consensus process. Investigators searched MEDLINE, Embase, and Cochrane CENTRAL for studies published after the STRIDE-II search period, then combined those findings with surveys of International Organization for the Study of IBD members and paediatric gastroenterologists from the Porto group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Of 13,071 records identified in the systematic review, 1018 were included. Surveys were completed by 60 of 79 IOIBD gastroenterologists and 23 of 30 paediatric gastroenterologists in the Porto group. Statements were then voted on using a modified Delphi approach, with consensus defined as at least 75% of participants rating a statement 7-10 on a 10-point scale.
A three-tier framework for Crohn’s disease and ulcerative colitis
The most consequential change is conceptual. STRIDE-III defines three distinct categories of treatment targets: actionable, adjunctive, and patient-centred. Each category carries a different clinical weight, and each answers a different question at the bedside.
Actionable targets are the ones that can reasonably trigger a therapeutic change. These include clinical response and clinical remission, which reflect patient priorities, along with objective inflammatory targets such as C-reactive protein normalisation, faecal calprotectin within target range, and endoscopic remission. The rationale is straightforward: if inflammation persists, mucosal injury continues, even when symptoms seem tolerable. Treating only the symptom burden risks accepting smouldering disease activity that can later translate into complications, hospitalisation, or irreversible bowel damage.
A short sentence carries a large clinical implication: symptoms alone are not enough.
By contrast, adjunctive targets are markers that matter, but do not automatically demand a switch in therapeutic class. These include urgency, histological remission in ulcerative colitis, transmural remission in Crohn’s disease, and growth. They help refine the intensity of follow-up and the degree of treatment optimisation. In practical terms, they can expose incomplete disease control even when the primary inflammatory target has improved. Their role is to sharpen decision-making rather than force a binary escalation threshold.
Patient-centred targets form a separate pathway. Disability, fatigue, and quality of life are not secondary afterthoughts in STRIDE-III; they are direct expressions of disease burden. These outcomes are impaired in a substantial proportion of patients with inflammatory bowel disease, and persistent impairment should prompt assessment of ongoing inflammation, alternative causes, and management through shared decision-making. The framework rejects a narrow laboratory-only model of disease control. If inflammation is quiet but fatigue, disability, or quality of life remain poor, the problem may lie in residual bowel disease, medication effects, psychological strain, nutritional deficits, or another non-inflammatory driver.
Timing now sits inside the target itself
STRIDE-III also organizes targets by time. Immediate, short-term, intermediate, and long-term goals are defined separately, rather than collapsing all outcomes into one undifferentiated endpoint. That sequencing matters because Crohn’s disease and ulcerative colitis do not respond on the same clock, and neither do biomarkers, symptoms, and mucosal healing.
This temporal structure has direct bedside value. A target that is appropriate in the first weeks of therapy may be different from the one expected months later. Similarly, the new framework defines treatment-specific times to target achievement, which should help clinicians interpret whether a patient is progressing as expected or lagging behind the anticipated response window. The result is a more disciplined approach to follow-up, especially when early biomarker improvement does not yet match symptom resolution or endoscopic recovery.
Faecal calprotectin thresholds and resource-limited adaptation
The updated statement set also introduces new faecal calprotectin thresholds and adaptations for resource-limited settings. Biomarker thresholds matter because they sit between symptoms and invasive assessment, offering a practical way to detect residual intestinal inflammation when endoscopy is not immediately available. A more precise biomarker target can reduce ambiguity in follow-up and improve consistency across clinics, although any threshold still has to be interpreted in the context of the individual patient and the disease phenotype.
Resource-limited adaptation is equally important. Not every setting can deploy the full spectrum of endoscopic, histologic, and transmural monitoring on demand. STRIDE-III explicitly addresses that reality by adapting the target framework so that evidence-based treat-to-target care remains usable even when local resources are constrained. This keeps the recommendations clinically relevant across different health systems rather than reserving them for highly specialised centres alone.
What changed for daily practice
The practical contribution of STRIDE-III is its separation of targets that should prompt treatment change from those that mainly guide optimisation and monitoring. That distinction is central to modern inflammatory bowel disease care, where overreaction to every abnormal marker can be as unhelpful as ignoring persistent objective inflammation. Clinicians now have a clearer hierarchy: move aggressively when actionable inflammatory targets remain unmet, tighten surveillance when adjunctive targets lag, and address disability, fatigue, and quality of life through a patient-centred process that includes shared decision-making.
The framework also strengthens alignment between adult and paediatric practice. Survey input from paediatric gastroenterologists was incorporated alongside adult specialist opinion, which is especially relevant in a disease where growth is one of the adjunctive targets and where long-term consequences of uncontrolled inflammation can accumulate across childhood and adolescence. A child with apparently mild symptoms may still need closer attention if growth is faltering or objective inflammation persists.
A more explicit contract between inflammation and lived experience
STRIDE-III does not claim that every target should be treated the same way. Instead, it creates a clearer contract between what is measured and what is acted upon. Objective inflammatory activity remains at the centre of treat-to-target care, but patient priorities now hold a more explicit place in the structure, and not as a vague add-on. The updated recommendations also acknowledge that the path from active inflammation to durable remission is not linear. Symptoms can improve before inflammation resolves, biomarkers can improve before tissue healing is complete, and quality of life can remain impaired long after intestinal inflammation appears controlled.
For clinicians, the implication is immediate: the next decision should depend on which target is being assessed, how quickly it should be reached, and whether failure to meet it should trigger a treatment change or a tighter monitoring plan. For patients, the benefit is a more transparent framework for why one marker leads to a medication change while another leads to closer observation. The remaining challenge is not whether treat-to-target care is useful. It is how consistently these categories are applied in everyday practice, especially when symptoms, biomarkers, and patient-reported burden do not point in the same direction.